Sameeksha Capital's founder is impressed by PSP Projects’ execution and capital efficiency
Rising chronic illnesses and increasing health insurance coverage will spur domestic pharma industry growth
The Indian pharma industry has a stellar decadal run and it’s not going to change anytime soon
Banking on acquisitions, Torrent Pharma is focused on strengthening its presence in the domestic market
What does the future of the third-party logistics industry look like in a post-GST world?
His bet on Natco Pharma’s differentiated product portfolio paid off while Monnet Ispat taught him to be wary of over-ambitious entrepreneurs
How the price of uncertainty threw up a great bargain in the form of Cadila Healthcare and how his relative bet on NTPC didn’t work out
Not content with the initial win in biosimiliars, Kiran Mazumdar-Shaw is pushing new frontiers in biologics
Four self-made entrepreneurs talked about their struggles and success mantra at Smart Enterprise Cluster Meet in Aurangabad — Part 2
Four self-made entrepreneurs talked about their struggles and success mantra at Smart Enterprise Cluster Meet in Aurangabad — Part I
The domestic pharma industry, which is already battling the US FDA, has now to contend with regulatory challenges at home
Textile and Pharma companies in Ahmedabad want clarity and stability in policy framework even as they battle short-term hiccups caused by demonetisation
Despite the excise tax exemptions ending in a couple of years, Baddi is still seen as a hospitable cluster
Sun Pharma has a robust pipeline in specialty business which will drive its profitability and free cash flow in the near future
The time has come for Shilpa Medicare to reap the benefits of the hard work done by its management over the past few years
Nilesh Shetty and Anand Shah on whether pharma stocks can make a comeback
Hyderabad’s pharma players are adapting to a regulatory backlash and fighting back against dumping from China
Pharma companies are giving OTC brands a makeover by splurging on advertising
Dilip Shanghvi holding on to what he has created even as his peers cash out shows his confidence in the business
A shift in focus in the US and the EU has propelled the stock price of Aurobindo Pharma to an all-time high
As their tax holiday draws to a close, many pharmaceutical units are unsure about their future in the hilly Baddi
A US hedge fund manager, is taking legal recourse to challenge drug patents of 15 companies
Betting on Indian equities solely based on the optimism of the government would be far from being prudent
Can Sun Pharma’s Dilip Shanghvi work his merger magic on Ranbaxy?
